These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 18063376)

  • 1. Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling.
    Torres-Peraza JF; Giralt A; García-Martínez JM; Pedrosa E; Canals JM; Alberch J
    Neurobiol Dis; 2008 Mar; 29(3):409-21. PubMed ID: 18063376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression.
    Giralt A; Rodrigo T; Martín ED; Gonzalez JR; Milà M; Ceña V; Dierssen M; Canals JM; Alberch J
    Neuroscience; 2009 Feb; 158(4):1234-50. PubMed ID: 19121372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
    Milnerwood AJ; Raymond LA
    J Physiol; 2007 Dec; 585(Pt 3):817-31. PubMed ID: 17947312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
    Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
    J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
    Farrar AM; Callahan JW; Abercrombie ED
    Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
    Li L; Murphy TH; Hayden MR; Raymond LA
    J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
    Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
    J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin.
    Parsons MP; Kang R; Buren C; Dau A; Southwell AL; Doty CN; Sanders SS; Hayden MR; Raymond LA
    J Biol Chem; 2014 Feb; 289(6):3518-28. PubMed ID: 24347167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.
    Li L; Fan M; Icton CD; Chen N; Leavitt BR; Hayden MR; Murphy TH; Raymond LA
    Neurobiol Aging; 2003 Dec; 24(8):1113-21. PubMed ID: 14643383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
    Zeron MM; Hansson O; Chen N; Wellington CL; Leavitt BR; Brundin P; Hayden MR; Raymond LA
    Neuron; 2002 Mar; 33(6):849-60. PubMed ID: 11906693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptor function in mouse models of Huntington disease.
    Cepeda C; Ariano MA; Calvert CR; Flores-Hernández J; Chandler SH; Leavitt BR; Hayden MR; Levine MS
    J Neurosci Res; 2001 Nov; 66(4):525-39. PubMed ID: 11746372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.
    Milnerwood AJ; Gladding CM; Pouladi MA; Kaufman AM; Hines RM; Boyd JD; Ko RW; Vasuta OC; Graham RK; Hayden MR; Murphy TH; Raymond LA
    Neuron; 2010 Jan; 65(2):178-90. PubMed ID: 20152125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors.
    Fan MM; Zhang H; Hayden MR; Pelech SL; Raymond LA
    J Neurochem; 2008 Feb; 104(3):790-805. PubMed ID: 17971125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.
    Zucker B; Luthi-Carter R; Kama JA; Dunah AW; Stern EA; Fox JH; Standaert DG; Young AB; Augood SJ
    Hum Mol Genet; 2005 Jan; 14(2):179-89. PubMed ID: 15548548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.
    Xifró X; Giralt A; Saavedra A; García-Martínez JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
    Neurobiol Dis; 2009 Dec; 36(3):461-9. PubMed ID: 19733666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.
    Kung VW; Hassam R; Morton AJ; Jones S
    Neuroscience; 2007 Jun; 146(4):1571-80. PubMed ID: 17478055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.